| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jiuyang Xu | Q64878619 |
| Xinquan Wang | Q90294415 | ||
| Linqi Zhang | Q91516083 | ||
| P2093 | author name string | Pengfei Wang | |
| Xuanling Shi | |||
| Senyan Zhang | |||
| Wenxu Jia | |||
| P2860 | cites work | Origin and evolution of pathogenic coronaviruses | Q87747946 |
| Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein | Q89568621 | ||
| Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset | Q91233428 | ||
| Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC | Q24329089 | ||
| Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia | Q24558699 | ||
| Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group | Q24604486 | ||
| Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5 | Q24632997 | ||
| Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 | Q27678981 | ||
| Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus | Q27680061 | ||
| Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor | Q27689029 | ||
| Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26 | Q27695604 | ||
| Identification of a new human coronavirus | Q29615906 | ||
| Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia | Q29618053 | ||
| Rapid generation of a mouse model for Middle East respiratory syndrome | Q30217177 | ||
| Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. | Q30359335 | ||
| Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. | Q30362113 | ||
| Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. | Q30368736 | ||
| Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. | Q30371303 | ||
| A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. | Q30378994 | ||
| A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. | Q30379384 | ||
| Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection | Q30399700 | ||
| DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice | Q30400066 | ||
| Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus | Q30400728 | ||
| A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein | Q30402347 | ||
| Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains | Q30845557 | ||
| Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution | Q33627189 | ||
| A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. | Q33743790 | ||
| The spike protein of SARS-CoV--a target for vaccine and therapeutic development | Q34015988 | ||
| Coronavirus spike proteins in viral entry and pathogenesis | Q34132548 | ||
| Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat | Q34261861 | ||
| Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design | Q34324907 | ||
| The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies | Q34653419 | ||
| Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation | Q35009468 | ||
| A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines | Q35063993 | ||
| Receptor recognition mechanisms of coronaviruses: a decade of structural studies | Q35115572 | ||
| Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. | Q54217812 | ||
| Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. | Q54241763 | ||
| International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials | Q56447686 | ||
| Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection | Q56558457 | ||
| Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets | Q56907500 | ||
| Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis | Q57794680 | ||
| A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV | Q58693121 | ||
| Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2 | Q58785257 | ||
| Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model | Q59358732 | ||
| Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in | Q61805218 | ||
| A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike | Q63246151 | ||
| A novel human mAb (MERS-GD27) provides prophylactic and postexposure efficacy in MERS-CoV susceptible mice | Q64136721 | ||
| Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient | Q64137589 | ||
| Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection | Q64374628 | ||
| A highly immunogenic, protective and safe adenovirus-based vaccine expressing MERS-CoV S1-CD40L fusion protein in transgenic human DPP4 mouse model | Q64374803 | ||
| Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein | Q35159147 | ||
| Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors | Q35857215 | ||
| Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection | Q35865538 | ||
| Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus | Q35887626 | ||
| Evaluation of candidate vaccine approaches for MERS-CoV. | Q35917397 | ||
| Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27 | Q35964208 | ||
| Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus | Q35989939 | ||
| Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. | Q36063562 | ||
| A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates | Q36069589 | ||
| Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge | Q36252666 | ||
| Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans | Q36432023 | ||
| Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease | Q36465731 | ||
| Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4. | Q36562859 | ||
| 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012 | Q36626864 | ||
| Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection | Q36816625 | ||
| Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection | Q37188934 | ||
| Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus | Q37264927 | ||
| One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus | Q37560824 | ||
| MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques | Q37706472 | ||
| The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection | Q39144823 | ||
| Replication-defective vector based on a chimpanzee adenovirus | Q39605384 | ||
| Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection | Q39677274 | ||
| Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. | Q40083207 | ||
| ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice | Q40173497 | ||
| Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset. | Q40215096 | ||
| Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. | Q40252744 | ||
| MERS-CoV spike nanoparticles protect mice from MERS-CoV infection | Q40317741 | ||
| Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding | Q40397876 | ||
| A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection | Q40503787 | ||
| Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice | Q40744757 | ||
| An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels | Q40867301 | ||
| Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein | Q41199088 | ||
| Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus | Q41242033 | ||
| Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice | Q41752133 | ||
| Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. | Q42152380 | ||
| Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies | Q42249511 | ||
| Origins and pathogenesis of Middle East respiratory syndrome-associated coronavirus: recent advances | Q42353676 | ||
| Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. | Q42612038 | ||
| A new virus isolated from the human respiratory tract | Q45825116 | ||
| Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model | Q47147430 | ||
| A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization | Q47288304 | ||
| Middle East respiratory syndrome. | Q51011540 | ||
| Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape. | Q51149122 | ||
| Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. | Q51660929 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | viral antibodies | Q66021534 |
| betacoronaviruses spike protein | Q81490886 | ||
| Coronavirus | Q290805 | ||
| monoclonal antibody | Q422248 | ||
| Middle East respiratory syndrome | Q16654806 | ||
| RNA virus infectious disease | Q18967413 | ||
| coronavirus disease | Q18975243 | ||
| P304 | page(s) | 841-856 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Emerging Microbes & Infections | Q27724513 |
| P1476 | title | Antibodies and vaccines against Middle East respiratory syndrome coronavirus | |
| P478 | volume | 8 |
| Q90550428 | 2019 novel Coronavirus outbreak: a quiz or final exam? |
| Q84316056 | Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein |
| Q90425437 | COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics |
| Q90744942 | COVID-19: what has been learned and to be learned about the novel coronavirus disease |
| Q89879578 | Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development |
| Q95851279 | Human neutralizing antibodies elicited by SARS-CoV-2 infection |
| Q87461749 | Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China |
| Q99240136 | Nanomedicine strategies to target coronavirus |
| Q90658009 | Pharmacologic Treatments and Supportive Care for Middle East Respiratory Syndrome |
| Q95262934 | Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells |
| Q94545219 | The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses |
| Q95933666 | Vulnerabilities in coronavirus glycan shields despite extensive glycosylation |
Search more.